SAN DIEGO, Sept. 1, 2016
SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in September, including: Rodman & Renshaw 18th Annual Global Investment Conference and Bioelectrics 2016: 13th International Bioelectrics Symposium.
Rodman & Renshaw 18th Annual Global Investment Conference
Punit Dhillon will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference on September 12 at 10:00 AM ET at The Lotte New York Palace Hotel in New York City. To view to the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/rrshq26/oncs/. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
This conference brings together growth companies and a vast audience of financial and strategic investors for in-depth corporate presentations as well as to facilitate one-on-one investor and networking meetings. The conference will focus on tracks dedicated to healthcare; natural resources; technology, media and telecommunications; clean tech. For more information, please visit: http://www.rodm.com.
Bioelectrics 2016: 13th International Bioelectrics Symposium
Richard Connolly, PhD, Director of Bioengineering at OncoSec, will present an invited lecture entitled: "Adaptive Electroporation Technology for Intratumoral Immunotherapy" at the 13th International Bioelectrics Symposium on September 12 at 9:45 AM CEST at the Penta Hotel in Rostock, Germany.
The symposium presents a forum to discuss research and applications regarding the interactions of electrical stimuli with living cells, in particular pulsed electric fields and non-thermal plasmas. Research topics and applications covered during the symposium include: biological responses; biophysics and biochemistry of interaction mechanisms; exposure devices and methods, and cancer treatment and tumor ablation. For more information, please visit: http://www.bioelectrics2016.org/.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. ImmunoPulse® IL-12, OncoSec's lead program, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
OncoSec Medical Incorporated
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-september-300321124.html
SOURCE OncoSec Medical IncorporatedPR Newswire
Last updated on: 01/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.